argenx (ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental Biologics License Application, sBLA, for VYVGART Hytrulo 1,000mg)/vial for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy, CIDP. VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only therapy approved in China for the treatment of CIDP, a debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Zai Lab, Argenx announce China NMPA approval for Vyvgart Hytrulo sBLA
- Scotiabank upgrades Argenx on Vyvgart upside, pipeline optionality
- Argenx upgraded to Outperform from Sector Perform at Scotiabank
- Argenx price target raised to EUR 620 from EUR 570 at JPMorgan
- Argenx price target raised to EUR 525 from EUR 500 at Deutsche Bank